Severe Cornea Damage
BRM423 is targeted to treat severe corneal damage
BRM423 is a novel synthetic peptide derived from human Pigment Epithelium-Derived Factor (PEDF). Its active ingredient is the same as the BRM421 for Dry Eye Disease, but it is targeted to treat severe corneal damage.
Based on BRIM’s proprietary PDSP platform, BRIM intends to rapidly advance the development of this novel treatment for corneal damage repair.
About Corneal Damage
When the cornea is damaged, corneal renewal and repair are supported by limbal stem cells (LSCs) that reside in the limbus. In cases where LSCs are insufficient or dysfunctional, corneal damage cannot be healed and may cause blindness. Losing LSCs due to diseases or accidents is a common cause of blindness.
Promote fast corneal healing
BRM423 has proven to promote fast corneal healing efficacy in pre-clinical studies. This novel neurotrophic peptide stimulates corneal wound healing and corneal repair. As a PEDF-derived short peptide (PDSP), BRM423 was previously shown to promote LSC regeneration in animal models. Furthermore, PDSP-expanded LSCs maintain their ability to differentiate into corneal cells as well as the ability to self-renewal. Most importantly, PDSP significantly accelerated corneal wound healing in animal models and demonstrated the corneal re-epithelialization function of PEDF, which may be via promoting LSC expansion. BRM423’s safety and early on-set efficacy were predicted based on the two clinical studies of BRM421 and we can leverage these data to enter the phase 2 clinical study soon.